|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (2015)) |
IUPAC Name ![]() |
| 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 7512 | flibanserin |
Synonyms ![]() |
| Addyi® |
| BIMT-17 |
| Girosa® (proposed trade name) |
Database Links ![]() |
|
| CAS Registry No. | 167933-07-5 |
| ChEMBL Ligand | CHEMBL231068 |
| DrugBank Ligand | DB04908 |
| PubChem CID | 6918248 |
| Search Google for chemical match using the InChIKey | PPRRDFIXUUSXRA-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | PPRRDFIXUUSXRA |
| Search PubMed clinical trials | flibanserin |
| Search PubMed titles | flibanserin |
| Search PubMed titles/abstracts | flibanserin |
| Wikipedia | Flibanserin |
| Comments |
| Flibanserin is reported as a serotonin 5-HT1A agonist and 5-HT2A antagonist [2]. The compound was originally investigated as a antidepressant [3-4]. |